ProQR Therapeutics BV Asset Resilience Ratio
ProQR Therapeutics BV asset resilience ratio. ProQR Therapeutics BV (PRQR) has an Asset Resilience Ratio of 0.00% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can ProQR Therapeutics BV fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of ProQR Therapeutics BV (2014–2023)
Asset resilience ratio of ProQR Therapeutics BV from 2014 to 2023. This chart shows how ProQR Therapeutics BV's Asset Resilience Ratio has changed over time. Read PRQR total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down ProQR Therapeutics BV's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is ProQR Therapeutics BV's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: ProQR Therapeutics BV maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
ProQR Therapeutics BV Industry Peers by Asset Resilience Ratio
Compare ProQR Therapeutics BV's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
ProQR Therapeutics BV Asset Resilience Ratio by Year (2014–2023)
ProQR Therapeutics BV asset resilience ratio by year from 2014 to 2023. The table below shows the annual Asset Resilience Ratio data for ProQR Therapeutics BV.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | -0.06% | $-98.05K | $152.31 Million | -- |
| 2019-12-31 | 0.00% | $0.00 | $131.93 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $110.23 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $63.77 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $69.13 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $108.75 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $139.45 Million | -- |
About ProQR Therapeutics BV
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic disea… Read more